Evidence map›Paper›PMID 36177448›Full record

ArticleCell genomics2022

A patient-driven clinicogenomic partnership for metastatic prostate cancer.

Jett Crowdis, Sara Balch, Lauren Sterlin, Beena S Thomas, Sabrina Y Camp, Michael Dunphy, Elana Anastasio, Shahrayz Shah, Alyssa L Damon, Rafael Ramos and 22 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell genomics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. RUNX1T1 drives stem-like small-cell neuroendocrine prostate cancer identity.Frontiers in cell and developmental biology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors at 5 institutions in 3 countries.

Jett CrowdisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Sara BalchDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Lauren SterlinBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Beena S ThomasBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Sabrina Y CampDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Michael DunphyBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Elana AnastasioBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Shahrayz ShahBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Alyssa L DamonBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Rafael RamosDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Delia M SosaBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Ilan K SmallBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Brett N TomsonBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Colleen M NguyenBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Mary McGillicuddyBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Parker S ChastainBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Meng Xiao HeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Alexander T M CheungDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Stephanie WankowiczBiophysics Graduate Program, University of California San Francisco, San Francisco, CA 94143, USA.
Alok K TewariDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Dewey KimDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Saud H AlDubayanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Ayanah DowdyeBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Benjamin ZolaBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Joel NowakCancer ABCs, Brooklyn, NY 11201, USA.
Jan ManariteCancer ABCs, Brooklyn, NY 11201, USA.
Idola Henry GunnFounder, MomVetWifeWidow.Org.
Bryce OlsonGlobal Strategist, Health and Life Sciences, Intel Corp, Patient Advocate, SequenceMe, Santa Clara, CA 95054, USA.
Eric S LanderBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Corrie A PainterBroad Institute of Harvard and MIT, Cambridge, MA 02142, USA.
Nikhil WagleDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Eliezer M Van AllenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02115, USA.
Broad Institute · USDana-Farber Cancer Institute · USSkin Cancer Foundation · USIntel (United States) · USUniversity of California, San Francisco · US

Funding

Participant Engagement UnitU2CCA252974 · NCI · BROAD INSTITUTE, INC. · PI MACK, JENNIFER W · 2020 to 2025
$16.6M
MOLECULAR BIOPHYSICS TRAINING GRANTT32GM008313 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI MURTHY, VENKATESH N · 1989 to 2023
$14.6M
Molecular and immune drivers of immunotherapy responsiveness in prostate cancerU01CA233100 · NCI · DANA-FARBER CANCER INST · PI FONG, LAWRENCE, VAN ALLEN, ELIEZER M · 2018 to 2022
$4.2M
Integrative Somatic and Germline Computational Biology to Redefine Clinical Actionability in Solid TumorsR01CA227388 · NCI · DANA-FARBER CANCER INST · PI VAN ALLEN, ELIEZER M · 2018 to 2022
$2.0M
NCI NIH HHS R01 CA227388NCI NIH HHS U01 CA233100NCI NIH HHS U2C CA252974NIGMS NIH HHS T32 GM008313
6 · The paper itself

Abstract

Molecular profiling studies have enabled discoveries for metastatic prostate cancer (MPC) but have predominantly occurred in academic medical institutions and involved non-representative patient populations. We established the Metastatic Prostate Cancer Project (MPCproject, mpcproject.org), a patient-partnered initiative to involve patients with MPC living anywhere in the US and Canada in molecular research. Here, we present results from our partnership with the first 706 MPCproject participants. While 41% of patient partners live in rural, physician-shortage, or medically underserved areas, the MPCproject has not yet achieved racial diversity, a disparity that demands new initiatives detailed herein. Among molecular data from 333 patient partners (572 samples), exome sequencing of 63 tumor and 19 cell-free DNA (cfDNA) samples recapitulated known findings in MPC, while inexpensive ultra-low-coverage sequencing of 318 cfDNA samples revealed clinically relevant

Identifiers

PMID36177448
PMCPMC9518748
OpenAlexW4295988800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.